

Nice & Green has contributed to the successful capital increase of NFL Biosciences with over EUR 3 million raised

Nyon Switzerland, 31 January 2023 – Nice & Green, the Swiss investment firm, has contributed to the very successful capital increase of NFL Biosciences (FR0014003XT0 – ALNFL), a biopharmaceutical company that is developing botanical drugs for the treatment of addictions.

The funds raised will support the financing for the CESTO II phase II/III trial, which aims to demonstrate the efficacy of its botanical drug candidate NFL-101 for smoking, and the PRECESTO trial, which explores the potential of NFL-101 in association with nicotine replacement therapies. Additionally, the funds will aid the continued progress of NFL-301, a project to reduce alcohol consumption.

Bertrand Schmitt, Managing Partner of Nice & Green said: “Nice & Green strongly supports the causes embraced by NFL Biosciences and believes in their continued success, which is why we participated in their capital increase.”

About Nice & Green

Nice & Green is a privately held Swiss funding firm, active in the European market providing smart funding solutions to listed Micro-, Small- and Mid-Cap companies supporting their growth as partners. Find out more at [nicengreen.ch](https://www.nicengreen.ch).

About NFL Biosciences

NFL Biosciences is a biopharmaceutical company based in the Montpellier area which develops botanical drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, natural, safer, and more effective therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, called NFL-101, is a standardized, nicotine free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorders. For more information, [nflbiosciences.com](https://www.nflbiosciences.com).

Contact Information

Morgane Henchoz
MarCom Specialist

+41 22 361 36 97
mhenchoz@nicengreen.ch